Feature | Structural Heart | August 12, 2019| Ashish Pershad, M.D., and Kenith Fang, M.D., FACS

National Coverage Determination Will Make TAVR Available to More Patients at More Centers

Valve technology and collaborative process have evolved over time

Example of an aortic valve CT imaging workup for TAVR valve sizing and assessing access routes. This patient has an aneurism in the aortic arch. Image from GE Healthcare.

Example of an aortic valve CT imaging workup for TAVR valve sizing and assessing access routes. This patient has an aneurism in the aortic arch. Image from GE Healthcare.

As we usher in a new era for treating patients with aortic stenosis, we have been reflecting on the evolution of the technology used for transcatheter aortic valve replacement (TAVR) and the evolution of our collaborative process as a team over years as a center in the PARTNER 3 clinical trial. PARTNER 3, which this year showed low-risk patients fared as well or better with TAVR as they did with surgery. This led to the broader National Coverage Determination (NCD) approved in June 2019, opening Medicare payments to most patients; and changes are coming to society guidelines and U.S. Food and Drug Administration (FDA) guidance, which will bring TAVR to more patients and centers.

Through three generations of valves, multiple clinical trials, surveillance through a national registry, and nearly a decade of experience, TAVR safety has steadily improved. The replacement valve technology has evolved along with our heart team’s approach all the way from evaluation of patients to the choice of TAVR or surgery, the procedure itself and follow up. 


Evolution of the TAVR technology
Manufacturers rapidly modified valves and the delivery sheaths from generation 1 to 3. First, delivery catheters became smaller, and the lower profile catheter is less likely to cause vascular injury.  Valves were also redesigned to have a skirt or a wrap around them, reducing the incidence of paravalvular leak, an Achilles heel of TAVR early on.


Evolution of the Collaborative Process
As the valves have evolved, so has our approach as a team to placing them. As surgeons, interventional cardiologists, general cardiologists, and imagers working together at Banner — University Medicine Heart Institute, we learned that planning is 90 percent of the procedure. At the same time, we have come to fully appreciate the need for strong collaboration focused around the needs of each patient. 

Moving from ultrasound to computed tomography (CT) scans to choose valve sizes was a significant early change in our process that helped us identify and prevent major complications, such as valve embolization. A CT angiogram (CTA) allows for better delineation of coplanar deployment angles to support proper valve positioning, which reduces the incidence of para valvular leaks. A CTA also provides information needed for careful assessment of access vessel quality and size, facilitating selection of the most suitable access for TAVR and minimizing the risk of vascular complications.

Personalizing choices for each patient is another part of our team process. For a small portion of patients, surgery remains the best choice. Certain anatomy is likely to lead to complications with TAVR, including when blood vessels in the groin are too small, when coronary height is too low, or when congenital abnormalities are found in the aortic valve. Surgery is also a better option when opening the chest is required for another reason, such as a concomitant blockage, the need for mitral valve replacement in addition to the aortic valve replacement, or when work is required on the aorta. 

It takes a well-developed team pulling together in the best interest of the patient to identify an individualized approach to aortic valve replacement, considering patient history and available imaging, while pushing aside motivations related to ego, money, or even uninformed patient preferences. 

Sometimes a well-functioning team will determine if a third choice is in the patient’s best interest, and that is to do nothing when it would be futile because the patient is likely to die from another condition. 

Editor’s note: Ashish Pershad, M.D., interventional cardiologist, and Kenith Fang, M.D., a cardiothoracic surgeon, collaborate at Banner – University Medicine Heart Institute in Phoenix, one of the centers that participated in the PARTNER 3 clinical trial. 

Watch an interview with Pershad in the VIDEO: Comparison Between Watchman vs. Amulet LAA Occluders


Related TAVR Content:

CMS Finalizes Updates to Coverage Policy for Transcatheter Aortic Valve Replacement

TAVR Operator and Hospital Requirements Outlined in 2018 AATS/ACC/SCAI/STS Expert Consensus

Interventional Imagers: The Conductors of the Heart Team Orchestra


Length of Stay Impacts TAVR Outcomes

VIDEO: Applications in Cardiology for 3-D Printing and Computer Aided Design — Dee Dee Wang, M.D.

Hospital Consolidation May Increase Access to TAVR, New Cardiac Technologies

VIDEO: Conscious Sedation for TAVR Procedures — Mario Goessl, M.D.

Recent Advances in Transcatheter Valve Technology

VIDEO: TAVR For Asymptomatic Severe Aortic Stenosis — Philippe Genereux, M.D.

How to Perform Transcaval TAVR Access — Adam Greenbaum, M.D.

VIDEO: Outcomes Following Urgent TAVR - Results from the TVT Registry — Sammy Elmariah, M.D.

TAVR Stands Equal to Surgical Valve Replacement

VIDEO: Clinical Outcomes With the Lotus TAVR Valve — Ted Feldman, M.D.

How to Build an Integrated Heart Team — Brijeshwar Maini, M.D., Brian Bethea, M.D.

VIDEO: TAVR for Degenerated Surgical Valves — Valve-in-Valve TAVR Procedures — Sammy Elmariah, M.D.

Advances in Heart Valve Technology in 2017




Related Content

People watch the presentation of the five-year EXCEL Trial data by Gregg Stone, M.D., live in the Abbott booth at TCT 2019. Abbott makes the Xience stent used in the trial, which compared equally with long term surgical outcomes. #TCT2019

People watch the live presentation of the five-year EXCEL Trial data by Gregg Stone, M.D., in the Abbott booth at TCT 2019. Abbott makes the Xience stent used in the trial, which compared equally with long-term CABG surgical outcomes. 

Feature | Cath Lab | October 03, 2019
October 3, 2019 – Five-year data from the EXCEL Trial showed patients with left main coronary disease treated with pe
Two Stents Implanted in Democratic Presidential Candidate Bernie Sanders, suffers chest pain
News | Cath Lab | October 02, 2019 | Dave Fornell, Editor
October 2, 2019 — Democratic presidential candidate Sen.
Bypass Surgery and Coronary Stenting Yield Comparable 10-Year Survival
News | Cath Lab | September 25, 2019
Ten-year survival rates are similar for bypass surgery and coronary stenting with drug-eluting stents in randomized...
Complete Revascularization Superior to Culprit Lesion-only Intervention
News | Cath Lab | September 10, 2019
An international randomized trial has shown that complete revascularization reduces major cardiovascular events...
The cath lab staff UH Portage Medical Center.

The cath lab staff UH Portage Medical Center.

Feature | Cath Lab | September 09, 2019 | Anjan Gupta, M.D., FACC, FSCAI
Primary percutaneous coronary intervention (PCI) is the preferred treatment for acute...
FDA Grants Shockwave Medical Breakthrough Status for Coronary Intravascular Lithotripsy
News | Cath Lab | September 03, 2019
Shockwave Medical Inc. has received Breakthrough Device Designation from the U.S. Food and Drug Administration (FDA)...
Compound Could Help Improve Heart Attack Recovery
News | Cath Lab | August 27, 2019
Imagine there were a drug that you could take soon after a heart attack that could reduce damage by protecting healthy...
New Alliance Announced Between Transcatheter Cardiovascular Therapeutics and VEITHsymposium
News | Cath Lab | June 20, 2019
VEITHsymposium and the Cardiovascular Research Foundation (CRF) announced an alliance between Transcatheter...
Overlay Init